Skip to Content
MilliporeSigma
All Photos(1)

Documents

T1810000

Tranexamic acid

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

trans-4-(Aminomethyl)cyclohexanecarboxylic acid, AMCA, AMCHA, HAKU, TAMCHA, Tranexamic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
H2NCH2C6H10CO2H
CAS Number:
1197-18-8
Molecular Weight:
157.21
Beilstein/REAXYS Number:
2207452
MDL number:
MFCD00001466
UNSPSC Code:
41116107
PubChem Substance ID:
329826687
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

tranexamic acid

manufacturer/tradename

EDQM

mp

>300 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

InChI key

GYDJEQRTZSCIOI-LJGSYFOKSA-N

Gene Information

human ... PLG(5340)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Tranexamic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 6

1 of 6

4-(Aminomethyl)benzoic acid 97%

Sigma-Aldrich

283746

4-(Aminomethyl)benzoic acid

Aprotinin from bovine lung lyophilized powder, 3-7 TIU/mg solid

Sigma-Aldrich

A4529

Aprotinin from bovine lung

Sigma-Aldrich

Sigma-Aldrich

605190-M

Thrombin, Human Plasma

Testosterone British Pharmacopoeia (BP) Reference Standard

BP1076

Testosterone

N-Succinyl-Ala-Ala-Ala-p-nitroanilide elastase substrate

Sigma-Aldrich

S4760

N-Succinyl-Ala-Ala-Ala-p-nitroanilide

Fibrinogen from human plasma 50-70% protein (≥80% of protein is clottable)

Sigma-Aldrich

F3879

Fibrinogen from human plasma

Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1969-1974 (2013-11-08)
Approximately one-third of patients undergoing total hip replacement surgery require one to three units of blood postoperatively. Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to control bleeding after total hip replacement. A topical application
Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1961-1968 (2013-11-08)
Approximately one-third of patients undergoing total knee replacement require one to three units of blood postoperatively. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that has been successfully used intravenously to stop bleeding after total knee replacement. A topical application
S Grassin-Delyle et al.
British journal of anaesthesia, 111(6), 916-924 (2013-07-25)
Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either
Kristen A Matteson et al.
Obstetrics and gynecology, 121(3), 632-643 (2013-05-03)
To compare the effectiveness of nonsurgical abnormal uterine bleeding treatments for bleeding control, quality of life (QOL), pain, sexual health, patient satisfaction, additional treatments needed, and adverse events. MEDLINE, Cochrane databases, and Clinicaltrials.gov were searched from inception to May 2012.
Case scenario: management of trauma-induced coagulopathy in a severe blunt trauma patient.
Jean-Stephane David et al.
Anesthesiology, 119(1), 191-200 (2013-03-22)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service